Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml

Iulia Andras, Nicolae Crisan, Stefan Vesa, Razvan Rahota, Florina Romanciuc, Andrei Lazar, Carmen Socaciu, Deliu Victor Matei, Ottavio De Cobelli, Ioan Stelian Bocsan, Radu Tudor Coman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCA) at first systematic biopsy. Patients & methods: Ninety serum samples from patients with suspicion for PCA were included. Targeted and nontargeted metabolomic analysis was performed. Results: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCA at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCA at biopsy. Conclusion: Metabolomic analysis can predict the outcome of the first systematic biopsy.

Original languageEnglish
Pages (from-to)1793-1800
Number of pages8
JournalFuture Oncology
Volume13
Issue number20
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Metabolomics
Prostate-Specific Antigen
Prostate
Prostatic Neoplasms
Biopsy
Serum
Area Under Curve

Keywords

  • biopsy
  • metabolomics
  • prediction score
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Andras, I., Crisan, N., Vesa, S., Rahota, R., Romanciuc, F., Lazar, A., ... Coman, R. T. (2017). Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml. Future Oncology, 13(20), 1793-1800. https://doi.org/10.2217/fon-2017-0078

Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml. / Andras, Iulia; Crisan, Nicolae; Vesa, Stefan; Rahota, Razvan; Romanciuc, Florina; Lazar, Andrei; Socaciu, Carmen; Matei, Deliu Victor; De Cobelli, Ottavio; Bocsan, Ioan Stelian; Coman, Radu Tudor.

In: Future Oncology, Vol. 13, No. 20, 01.08.2017, p. 1793-1800.

Research output: Contribution to journalArticle

Andras, I, Crisan, N, Vesa, S, Rahota, R, Romanciuc, F, Lazar, A, Socaciu, C, Matei, DV, De Cobelli, O, Bocsan, IS & Coman, RT 2017, 'Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml', Future Oncology, vol. 13, no. 20, pp. 1793-1800. https://doi.org/10.2217/fon-2017-0078
Andras, Iulia ; Crisan, Nicolae ; Vesa, Stefan ; Rahota, Razvan ; Romanciuc, Florina ; Lazar, Andrei ; Socaciu, Carmen ; Matei, Deliu Victor ; De Cobelli, Ottavio ; Bocsan, Ioan Stelian ; Coman, Radu Tudor. / Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml. In: Future Oncology. 2017 ; Vol. 13, No. 20. pp. 1793-1800.
@article{316dd74f8e434fe786895db0e8b8c959,
title = "Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml",
abstract = "Aim: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCA) at first systematic biopsy. Patients & methods: Ninety serum samples from patients with suspicion for PCA were included. Targeted and nontargeted metabolomic analysis was performed. Results: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCA at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95{\%}, Sp 64.52{\%} for the detection of PCA at biopsy. Conclusion: Metabolomic analysis can predict the outcome of the first systematic biopsy.",
keywords = "biopsy, metabolomics, prediction score, prostate cancer",
author = "Iulia Andras and Nicolae Crisan and Stefan Vesa and Razvan Rahota and Florina Romanciuc and Andrei Lazar and Carmen Socaciu and Matei, {Deliu Victor} and {De Cobelli}, Ottavio and Bocsan, {Ioan Stelian} and Coman, {Radu Tudor}",
year = "2017",
month = "8",
day = "1",
doi = "10.2217/fon-2017-0078",
language = "English",
volume = "13",
pages = "1793--1800",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "20",

}

TY - JOUR

T1 - Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml

AU - Andras, Iulia

AU - Crisan, Nicolae

AU - Vesa, Stefan

AU - Rahota, Razvan

AU - Romanciuc, Florina

AU - Lazar, Andrei

AU - Socaciu, Carmen

AU - Matei, Deliu Victor

AU - De Cobelli, Ottavio

AU - Bocsan, Ioan Stelian

AU - Coman, Radu Tudor

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Aim: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCA) at first systematic biopsy. Patients & methods: Ninety serum samples from patients with suspicion for PCA were included. Targeted and nontargeted metabolomic analysis was performed. Results: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCA at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCA at biopsy. Conclusion: Metabolomic analysis can predict the outcome of the first systematic biopsy.

AB - Aim: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCA) at first systematic biopsy. Patients & methods: Ninety serum samples from patients with suspicion for PCA were included. Targeted and nontargeted metabolomic analysis was performed. Results: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCA at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCA at biopsy. Conclusion: Metabolomic analysis can predict the outcome of the first systematic biopsy.

KW - biopsy

KW - metabolomics

KW - prediction score

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85028554487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028554487&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0078

DO - 10.2217/fon-2017-0078

M3 - Article

VL - 13

SP - 1793

EP - 1800

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 20

ER -